December 16, 2020
1 min watch
Save
Expert: Combination therapies are ‘standard of care’ for RCC
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, Elizabeth Plimack, MD, chief of the division of genitourinary medical oncology at Fox Chase Cancer Center, discussed the use of combination therapies for treatment of renal cell carcinoma.
Clinicians “really can’t lose,” she said, if they are opting for one of the National Comprehensive Cancer Network-recommended preferred therapies — as long as they consider the data and identify treatment priorities.
Ultimately, though, the fact that combination therapies are now “standard of care” is the most important point, Plimack said.
Click here to watch the next video in the series on new treatment options for RCC.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interview
Disclosures:
Plimack reports serving as a scientific advisor for Bristol-Myers Squibb, Genentech, MEI, Merck and Seattle Genetics; conducting data safety monitoring for AstraZeneca, Pfizer and Infinity Pharma; receiving honorarium for CME presentations from ASCO GU, Clinical Care Options, Fox Chase Cancer Center, Mt. Sinai Icahn School of Medicine, NCCN, The Ohio State University, OncLive, PER, Research to Practice, Spire Learning and University of Hawaii; and receiving grants for clinical research from Astellas, Bristol-Myers Squibb, Genentech and Merck.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.